Literature DB >> 920871

Morphogenesis of fibrosis and cirrhosis in methotrexate-treated patients with psoriasis.

A Nyfors, H Poulsen.   

Abstract

Serial liver biopsies before and after Methotrexate therapy were performed in each of eight patients with severe, recalcitrant psoriasis treated for years with Methotrexate in a single, weekly, oral dose not exceeding 25 mg per dose. A total of 31 liver biopsies was studied. The study revealed liver damage commencing with small foci of piecemeal necrosis, followed by the destruction of the limiting plate and the occurrence of stellate periportal fibrosis. Eventually, partial and then whole fibrous septa developed between portal tracts and between portal tracts and central veins, with resultant distortions of the lobular architecture. In two patients with an admitted daily alcoholic intake, additional findings were seen, including alcoholic hepatitis, centrilobular fibrosis and development of partial and whole fibrous septa between the central vein area, and portal tracts adding to the number of septa running between the portal tracts and central veins which split up the lobules. The following conclusions seem probable: 1) Methotrexate therapy in psoriatics may cause development of fibrosis or cirrhosis; 2) the morphological changes during this development follow a consistent pattern; and 3) the pathogenesis of the development of fibrosis and cirrhosis is mixed in some cases, being dependent on both alcoholic and Methotrexate intake.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 920871     DOI: 10.1097/00000478-197709000-00005

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  6 in total

Review 1.  Hepatotoxicity of methotrexate in rheumatic diseases.

Authors:  S Kevat; M Ahern; P Hall
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 May-Jun

2.  Pathology of the liver with bone marrow transplantation. Effects of busulfan, carmustine, acute graft-versus-host disease, and cytomegalovirus infection.

Authors:  W E Beschorner; J Pino; J K Boitnott; P J Tutschka; G W Santos
Journal:  Am J Pathol       Date:  1980-05       Impact factor: 4.307

3.  A liver fibrosis cocktail? Psoriasis, methotrexate and genetic hemochromatosis.

Authors:  Joseph Mathew; May Y Leong; Nick Morley; Alastair D Burt
Journal:  BMC Dermatol       Date:  2005-11-29

4.  Effect of methotrexate on homocysteine and other sulfur compounds in tissues of rats fed a normal or a defined, choline-deficient diet.

Authors:  A M Svardal; P M Ueland; R K Berge; A Aarsland; N Aarsaether; P E Lønning; H Refsum
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 5.  [Quality and quantity in hepatopathology. Diagnostic and clinically relevant grading for non-tumourous liver diseases].

Authors:  T Longerich; C Flechtenmacher; P Schirmacher
Journal:  Pathologe       Date:  2008-02       Impact factor: 1.011

6.  Two methods of assessment of methotrexate hepatotoxicity in patients with rheumatoid arthritis.

Authors:  P D Hall; M J Ahern; L R Jarvis; P Stoll; M A Jenner; H Harley
Journal:  Ann Rheum Dis       Date:  1991-07       Impact factor: 19.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.